Dr. Nidhi Jalan-Sakrikar, Ph.D., is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, with a joint appointment in the Department of Biochemistry & Molecular Biology. She leads an independent research program focused on immune-mediated mechanisms that drive inflammation and fibrosis in PSC, a chronic cholestatic liver disease characterized by progressive bile duct injury.
I received my MD at Russian University of Friendship, Moscow. I then studied biochemistry and immunology during my graduate studies at Christian-Albrecht University, Germany. As a postdoctoral fellow at Columbia University (USA), I studied signal transduction, and expanded my skills in transgenic mouse technologies. I joined UCSD as a principal investigator. The major interest of my research is the identification of new targets for the therapy of MASH and MetALD-associated liver fibrosis and cholestatic fibrosis.
Dr. Yasuko Iwakiri is a Professor of Medicine at Yale School of Medicine, specializing in liver fibrosis, cirrhosis, and portal hypertension, with a focus on the vascular system, including lymphatics and liver endothelial cells. Her research also investigates endothelial-immune cell interactions, particularly macrophages, in alcohol-associated liver disease. She currently serves as an Associate Editor for the Journal of Hepatology and has previously held editorial roles with Hepatology and Hepatology Communications.
Consultant hepatologist at Hospital Clinic Barcelona, Associate professor at University of Barcelona
Dr. Craig Lammert is an Associate Professor of Medicine at Indiana University and an adult hepatologist specializing in autoimmune liver diseases, with a particular focus on autoimmune hepatitis (AIH). His clinical and translational research program centers on advancing the understanding of AIH through studies involving genetics, biomarkers, autoantibodies, and high-dimensional proteomic platforms. He is an active clinical investigator dedicated to improving therapeutic development and clinical trial design in AIH.
Imran Hasanoglu is an Associate Professor of Infectious Diseases and Clinical Microbiology at Ankara Yildirim Beyazit University School of Medicine, Turkiye, and the lead infectious diseases physician for the kidney transplant unit at Ankara Bilkent City Hospital.
Ming-Lung Yu is the President and a Chair Professor of Kaohsiung Medical University (KMU), Taiwan. He is also an adjunct chair professor of National Sun Yat-sen University(NSYSU). Professor Yu's research interests in Hepatology, including epidemiology, natural course, risk stratification, treatment and prognosis of HBV and HCV, as well as MASLD, have led him to publish more than 550 scientific original and review articles.
Dr. Nguyen is Professor of Medicine, a Stanford Cancer Institute member and specializes in the treatment and prevention of primary liver cancer such as hepatocellular carcinoma (HCC).
Dr. Yao-Chun (Holden) Hsu is currently Professor of Medicine at I-Shou University, and also the Director of the Department of Medical Research at E-Da Hospital in Kaohsiung, Taiwan. Beyond his dedication to front-line patient care, Dr. Hsu is committed to clinical and translational research in liver diseases, emphasizing viral hepatitis, with a special focus on chronic hepatitis B. He spearheads the hepatitis B research team at E-Da Hospital and fosters collaborations with researchers globally.
I am a physician-scientist and hepatologist at the University of Southern California with a research interest in Drug-Induced Liver Injury and Autoimmune Liver Diseases. I study mechanisms of liver injury and hepatotoxicity with a particular focus on cell death pathways using basic, animal model, and translational approaches. My lab currently focuses on Immune-mediated Liver Injury from Checkpoint Inhibitors and the complex interplay if signaling mechanisms leading to hepatotoxicity in immunotherapy.